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CHAPTER 1
INTRODUCTION
Traumatic brain injuries (TBI) constitute a significant proportion of accidental death and
long-term disability each year, resulting in an urgent need for treatment strategies that can be
delivered post-injury and reduce long-lasting symptoms to improve quality of life. It is estimated
that the United States experiences over 1.5 million TBIs each year, with 223,050 injuries leading
to TBI-related hospitalizations recorded in 2018 (Centers for Disease Control and Prevention,
2022). Mild TBI (mTBI) represents the most common subset of TBI and accounts for as much as
75% of total TBIs experienced annually (National Center for Injury Prevention and Control,
2003). It has also been shown that prior TBI significantly increases the risk of recurrent TBI and
that sustaining another mTBI during the vulnerable recovery period after an initial mTBI can
result in worsened outcomes, making repetitive mild TBI (rmTBI) a prominent topic of interest
(Lasry et al., 2017; Prins et al., 2013). While symptomology after mTBI may include varying
degrees of physical, cognitive, emotional, and sleep-related symptoms, vestibular impairment is
estimated to occur in nearly 80% of all injuries, with almost half of all TBI patients experiencing
dizziness or imbalance five years after injury (Marcus et al., 2019; Berman & Fredrickson,
1978). The cryptic nature of vestibular symptoms after mTBI makes diagnosis a challenging
clinical problem that often results in delayed treatment and care. There are no current
pharmaceutical interventions directed at attenuating the root cause of vestibular impairment after
mTBI. One of the only treatments available for vestibular dysfunction is vestibular rehabilitation
therapy, which requires extensive time, commitment, and financial resources. Thereby, the lack
1
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of targeted therapies for individuals suffering from long-term vestibular impairment after mTBI
remains a prominent clinical issue with high potential for therapeutic value.
Testosterone (T) treatment following injury has been shown to induce a diverse array of
neuroprotective and neurotherapeutic effects. Studies investigating testosterone treatment have
demonstrated reductions in mitochondrial dysfunction and neurodegeneration, inhibition of
oxidative stress, promotion of neurite outgrowth, and increases in interneural arborization
(Carteri et al., 2019; Wang, L. et al., 2019; Monaco et al., 2014; Fargo et al., 2009). Androgen
receptors, the respective receptors for testosterone, are present throughout the brain and
specifically in the vestibular nucleus, the principal area responsible for governing vestibular
function (Grassi et al., 2013). Previous research from the Foecking Lab has demonstrated that
testosterone administration following rmTBI improved vestibular deficiencies measured through
a robust vestibular battery (Segismundo, 2019).
While the therapeutic effects of testosterone are experientially well-supported, the time of
treatment evaluated in preclinical models has limited translatability to clinical situations
regarding mTBI. Given that most symptoms after mTBI resolve with time, clinical
recommendations post-mTBI advise against immediate treatments and suggest patients selfmonitor symptoms while they recover (Marshall et al., 2012). However, the lingering symptoms
that cease to recover with time may consequentially reduce quality of life and encourage patients
to seek treatments several weeks to months post-injury (Kim, K. & Priefer, 2020). Animal
models investigating mTBI rarely consider the effects of delayed treatments and thereby
overlook the clinical timeframe at which mTBI patients would receive a therapeutic agent.
Previous work in the Foecking Lab has demonstrated that delayed systemic testosterone after
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rmTBI can reduce the long-term severity of vestibular behavioral impairments and improve
neuronal survival in the vestibular nucleus (Foecking et al., 2022). While these findings support
the neurotherapeutic nature of delayed testosterone treatment, the molecular mechanism by
which testosterone ameliorates vestibular deficiencies and improves neuronal survival at
extended timepoints after injury remains widely unexplored.
Hypothesis
This thesis hypothesizes that repetitive mild TBI induces long-term molecular alterations
in the vestibular nucleus that regulate oxidative stress, protein folding, neuroregeneration, and
apoptosis and that delayed systemic testosterone ameliorates the sustained molecular
consequences of injury.
Specific Aims
Specific Aim 1: Determine if a well-established model of rmTBI can induce mRNA
alterations in apoptotic, cellular stress, and regenerative pathways at various chronic timepoints
after injury and how delayed testosterone treatment may alter mRNA expression after rmTBI.
Specific Aim 2: Investigate if a well-established model of rmTBI can induce protein
changes in apoptotic, cellular stress, and regenerative pathways at various chronic timepoints
after injury and how delayed testosterone treatment may alter protein levels after rmTBI.
Experimental Overview
In order to test this hypothesis, a previously established closed-head model of rmTBI was
utilized on eight-week-old male Long-Evans Hooded rats (Segismundo, 2019). This model has
been shown to induce chronic vestibular impairment via a vestibular battery and serves to mimic
the effects of repetitive mild TBI in a male human population. All rats, except sham, received
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five mTBIs spaced 48 hours apart via a controlled cortical impact (CCI) device, and all animals,
regardless of sham or rmTBI, were administered anesthesia prior to insult. Thirty-five days postinjury (DPI), a subset of rmTBI rats received an implantable testosterone capsule to mimic
systemic testosterone treatment at a clinically relevant timepoint. The brains of all three groups
(sham, rmTBI, and rmTBI + T) were then harvested either 0, 2, 7, or 28 days after testosterone
treatment, corresponding to 35, 37, 42, and 63 DPI. The vestibular nuclei were dissected,
homogenized, and processed for future analysis. Brain homogenates were extracted for mRNA
analysis via reverse transcription quantitative real-time polymerase chain reaction (RT-qPCR)
and protein analysis via western blotting.
This study helps uncover the molecular alterations associated with rmTBI in the
vestibular nucleus at clinically translational timepoints after injury. In doing so, it also
investigates how delayed treatment of testosterone, an endogenous gonadal steroid, may act
mechanistically to attenuate cellular death and thereby improve neuronal survival post-insult.
This research is the first of its kind to specifically investigate the long-term molecular changes
associated with rmTBI in the vestibular nucleus, with the aim to establish potential
pharmaceutical targets that may attenuate the chronic vestibular deficits often observed in
patients who suffer from rmTBI. Future research may use the findings from this thesis to
establish clinically relevant pharmaceutical targets that relieve vestibular symptomology when
delivered at delayed timepoints after injury.
Significance Statement
Globally, 69 million individuals suffer from TBI each year, with mild TBI being the most
common severity. A frequent symptom of mild TBI is vestibular dysfunction, which can often
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manifest into chronic vestibular impairments that severely reduce patient quality of life. There
are currently no pharmaceutical interventions targeted at treating the root cause of vestibular
dysfunction. Most mild TBI research delivers pharmaceutical interventions minutes to hours
after injury; however, this does not correspond with the timescale that patients typically seek
medical assistance. This thesis aims to uncover the long-term molecular alterations in oxidative
stress, neuroinflammation, and cellular death in the vestibular nucleus after repetitive mild TBI
and provide insight into the mechanistic pathways by which systemic testosterone can act as a
neurotherapeutic agent after injury.

CHAPTER 2
LITERATURE REVIEW AND BACKGROUND
Traumatic Brain Injury
A TBI is defined by the Centers for Disease Control and Prevention as a bump, blow, jolt
to the head, or a penetrating injury to the head, that disrupts the normal function of the brain. It is
estimated that 1.5 million TBIs occur annually, making TBI a contributing factor to nearly a
third of injury-related deaths in the United States alone (Faul et al., 2010). TBIs are classified as
unintentional injuries that most frequently occur from accidental falls, vehicle-related collisions,
violence, sport-related injuries, explosive blasts, and intentional self-harm (Centers for Disease
Control and Prevention, 2021). The unintentional nature of TBI puts the entire population at risk;
however, specific populations, such as men, the elderly, children, athletes, military personnel,
and victims of abuse, have a greater risk of experiencing TBI due to age-related circumstances
and lifestyle habits (Cassidy et al., 2004). The broad nature of injury makes TBI a complex
physical insult that can be categorized into various classes based on impact mechanism, number
of insults, and severity. Symptoms after TBI can be highly variable but often manifest through a
spectrum of physical, emotional, cognitive, and sleep-related disturbances, thereby making TBI
diagnosis and treatment a challenging clinical problem (Centers for Disease Control and
Prevention, 2015).

6
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Categorization of TBI
TBI classification is based on the physical nature of impact: 1.) direct impact injuries, 2.)
acceleration-deceleration injuries, and 3.) blast wave injuries. Direct impact injuries occur when
an object makes direct contact with the brain, usually penetrating the skull, thereby resulting in
visible focal damage such as brain contusion and epidural hematoma. Acceleration-deceleration
injuries are the most common mechanisms of injury and occur when the head is struck, or strikes
an object, but no penetrating injury occurs. The main impact in acceleration-deceleration injuries
results from sudden changes in momentum that forcefully move the brain within the confines of
the skull and cause diffuse injuries such as subdural hematoma and axonal shearing. To a lesser
extent, shock wave injuries occur when supersonic blast waves travel through the skull and into
the brain to create alterations in pressure that are responsible for injury (Saatman et al., 2008;
Rutter et al., 2021; Ma, X. et al., 2019).
After determining the mechanism of impact, one of the most essential classifications of
TBI is the severity of injury, which is divided into mild, moderate, and severe. Injury severity is
a crucial determinant of the potential consequences of insult, whether an individual seeks
medical attention, and the treatment paradigm for recovery. While there are several methods of
clinically diagnosing TBI, the most prevalent is the Glasgow Coma Scale (GCS), which analyzes
eye, verbal, and motor responses to assess consciousness (Teasdale & Jennett, 1974). GCS
scores of 13-15 are interpreted as mild TBI, GCS scores of 9-12 are interpreted as moderate TBI,
and GCS scores of 8 or less are interpreted as severe TBI. Since the introduction of the GCS,
many other clinical factors, such as loss of consciousness or posttraumatic amnesia, have also
been utilized to assist in the diagnostic categorization of TBI. Developments in neuroimaging
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techniques, particularly in computed tomography and magnetic resonance imaging, have also
contributed to the diagnosing of TBIs by providing evidence of intracranial damage in scenarios
where external cranial damage is unremarkable (Douglas et al., 2018).
Mild TBI
mTBI, often called concussion, makes up the highest proportion of TBI cases, composing
about 80% of all injuries. However, it is estimated that mTBI is often underdiagnosed and
underreported, thereby increasing the potential incidence of mTBI worldwide (Cassidy et al.,
2004). Failure to diagnose or report mTBI stems from the heterogeneous and cryptic
symptomology associated with the neurological injury, some of which include alterations in
sleep patterns, irritability, anxiety, difficulty concentrating, changes in memory recall, nausea,
dizziness, and balance impairments (Centers for Disease Control and Prevention, 2015). A
unique aspect of mTBI is that victims typically do not lose consciousness but rather enter a brief
dazed or confused state, making mTBI diagnosis reliant on self-reporting and difficult to identify
definitively. While the impact of mTBI has instantaneous consequences, there are instances
where symptoms do not develop until delayed timepoints after injury, thus creating scenarios
where individuals that experienced mTBI may not realize the severity of their injury until days or
weeks post-impact. Moderate and severe TBI are associated with tremendous neurological
consequences that are clinically identifiable via traditional neuroimaging techniques and often
remain unresolved for years after initial insult.
Primary & Secondary Injury
Regardless of type or severity, a commonality across all varieties of TBI is the primary
and secondary injuries associated with impact. The primary injury is the result of direct damage
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to the neural tissue from the mechanical forces associated with TBI (Maas et al., 2008). Primary
injuries are defined as the tearing of axonal fibers, contusion, hemorrhage, and shearing of
neurovasculature that occurs when the brain experiences tremendous forces from the initial
impact (Gaetz, 2004). The primary injury is associated with direct damage at the site of impact
and can vary in severity based on the magnitude of force produced upon impact. This initial
insult is considered the “unpreventable” aspect of TBI and can only be dampened by external
measures such as protective headwear or changes in lifestyle choices.
Once the primary injury occurs, it initiates the secondary injury, classified as the array of
metabolic, cellular, and mechanistic changes that arise after an initial impact. Secondary injuries
are much more diffuse than their primary counterparts and can affect regions of the brain that are
distant from the site of impact. Secondary injuries are defined as biochemical cascades that can
result from alterations in metabolic processes related to excitotoxicity, oxidative stress,
apoptosis, neuroinflammation, axonal demyelination, and alterations in blood flow (Bramlett &
Dietrich, 2015). The secondary injury is considered the treatable aspect of TBI and the injury of
focus when developing various therapeutic interventions for victims of TBI.
Repetitive mTBI
Given that mTBI is regarded as the least severe form of TBI, a unique concern to mTBI
injuries is that individuals often acutely resume activities that increase their risk of sustaining
subsequent mTBI. In a self-reporting study of over 2,900 college football players, athletes that
reported having three or more mTBIs were three times as likely to sustain another mTBI
compared to athletes who reported no history of mTBI (Guskiewicz et al., 2003). The increased
risk after mTBI may be attributed to a “window of vulnerability,” defined as a vulnerable time
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period where individuals are at increased risk for subsequent injury, increased symptoms
severity, and slower recovery (McCrea et al., 2009). The compound nature of impacts after
rmTBI leads to worsened outcomes for individuals who sustain multiple mTBI in an acute time
frame. A study examining middle and high school athletes revealed that those who received
rmTBI performed worse on sustained attention and executive function tasks compared to those
that only received a singular impact (Wall et al., 2006). Another study analyzing the temporal
window between two mTBI impacts revealed that a subsequent impact within five days of the
first impact can exacerbate the metabolic consequences associated with the initial insult
(Vagnozzi et al., 2007). These data reveal that rmTBI is of significant concern in individuals who
are at risk of mTBI and that the consequences of rmTBI can lead to worsened behavioral and
physiological outcomes.
Animal Models of TBI
Given the complexity of symptoms associated with TBI, most traumatic brain injury
research is conducted using various forms of animal models, with mouse and rat being the most
prominent. These models investigate various subcategories of TBI by exposing the animal to
inducible head trauma and then analyzing physiological changes or testing therapeutic options
after the insult. Animal models allow researchers examining TBI to closely mimic the forces
associated with insult and monitor the holistic functional changes that occur after injury, which is
not currently possible using in vitro or in silico modeling approaches. The use of animal models
in TBI research has grown tremendously in the past two decades, thereby highlighting
advancements aimed at better understanding such a complex and heterogenous injury.
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The method of inducing TBI is highly dependent on the type of injury a researcher is
aimed at studying. For example, blast injuries typically expose an animal to shock waves, while
direct impact injuries classically expose an animal to a controlled impact to the head or directly
to the brain. Given that acceleration-deceleration injury is the most frequently occurring
mechanism of head trauma, the vast majority of TBI research investigates this classification of
injury. TBI models can be subclassified into two categories, open-head injury and closed-head
injury. Open head injuries allow researchers to target specific brain regions through a cranial
window and make focal lesions to the areas of interest. While open-head models are more
precise and require less impact, the use of a craniotomy makes them less clinically relevant
compared to their closed-head counterparts. Closed-head models of TBI are designed to mimic
the forces that an individual would experience from a non-penetrating TBI. These models
routinely place an animal in a stereotaxic frame and expose the animal to an external force that
impacts the skull. Closed-head models are common when investigating less severe forms of TBI
because they mimic injury without introducing invasive craniotomies (Ma, X. et al., 2019).
The three most common approaches of inducing a TBI are fluid percussion, weight drop,
and controlled impact models. Fluid percussion models produce an injury by exposing the brain
to an increase in fluid pressure via a small cranial window. While fluid percussion models are
well-established and repeatable, they are the most invasive model due to the requirement of
performing a craniotomy, thereby always falling into the open-head model classification. The
weight drop model of TBI can be performed open-headed or close-headed and involves exposing
the rodent to a guided free-falling weight to drop from a known height on the head or brain of the
animal. Weight drop models are by far the oldest and most common models of TBI; however,
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they have shown to produce variable severities of TBI due to inconsistent combinations of
parameters across researchers. The most recently established and reliable model of TBI is the
CCI. A CCI model uses a piston to deliver an impact to the animal’s skull or brain of known
magnitude and velocity. This model can be performed open- or closed-head and has been shown
to create replicable impacts between animals by allowing for easy adjustment of known
parameters to investigate various severities of TBI (Ma, X. et al., 2019).
Behavioral Consequences of mTBI
The diffuse nature of mTBI creates a myriad of clinical symptoms that include alterations
in somatic, cognitive, and affective disturbances. The most commonly reported symptoms
associated with mTBI are headache, dizziness, nausea, fatigue, sleep-related disturbances, and
sensitivity to light (Prince & Bruhns, 2017). Frequent cognitive-related symptoms include
difficulty in memory and attention, lethargic processing speed, trouble with multitasking, and
heightened distractibility. Prevalent affective symptoms include irritability, anxiety, and
depression (Katz et al., 2015). Many of the symptoms associated with mTBI, regardless of
category, are considered multidimensional and may exacerbate or maintain other symptoms if
they continue to persist (Wood et al., 2014). While mTBI symptoms are often considered acute
and reside within 14 days post-injury (Iverson, 2005), prolonged symptoms are observed in 1020% of patients who continue to report detrimental symptoms months to years after initial impact
(Ruff, 2005; Alexander, 1995). As one can presume, sustained symptoms after mTBI have the
potential to contribute to morbidity, create enormous financial burden, and severely impact a
patient’s quality of life.
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Vestibular Dysfunction
A particularly interesting symptomatic phenomenon after mTBI is vestibular dysfunction,
which can encompass several symptoms including vertigo, dizziness, balance impairment, and
dampened proprioception. Studies that have attempted to document chronic vestibular
impairment after mild to moderate TBI have yielded findings ranging from 32-65%, which
indicated that persistent vestibular deficits are much more common than other prolonged
symptoms (Berman & Fredrickson, 1978; Gannon et al., 1978; Willson et al., 1981). More recent
evidence shows that due to the broad nature of vestibular symptoms, patients deny or underreport
vestibular dysfunction, thereby potentially increasing the incidence of vestibular deficits postinjury (Marcus et al., 2019).
The origins of vestibular impairment can be subdivided into peripheral and central
impairment. Peripheral impairment stems from damage to the peripheral end organ, labyrinth, or
vestibulocochlear nerve. Central impairment is much broader and originates from damage to the
vestibular nucleus, an area located in the brainstem that receives afferent vestibular information
(Murray et al., 2017). Damage to either, or both, peripheral and central vestibular system can
result in clinical manifestations observed in TBI; however, brain-related (central) vestibular
impairment is the focus of this master’s thesis as prior work in the Foecking Lab as demonstrated
neuronal loss in the vestibular nucleus at chronic timepoints after rmTBI (Segismundo, 2019).
The vestibular nucleus is a brain region in the hindbrain that extends from the rostral
medulla to the caudal pons. The vestibular nucleus is a composition of four nuclei: 1.) lateral
vestibular nucleus, 2.) medial vestibular nucleus, 3.) superior vestibular nucleus, 4.) descending
(inferior) vestibular nucleus. Collectively the vestibular nuclei are highly interconnected and
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project complex fibers to the contralateral vestibular nuclei, thalamus, cerebellum, spinal cord,
and motor nuclei of the extraocular muscles. The vestibular nucleus has been shown to be
functionally implicated in maintaining equilibrium, posture, head position, and coordinating
vision with corresponding head movements. Damage to the vestibular nucleus can occur from
diffuse secondary injury seen with brain trauma and result in the clinically related symptoms
observed in mTBI (Hernandez & Das, 2022).
Pathology of TBI
The pathological consequences of TBI have been shown to manifest through a range of
acute and chronic behavioral outcomes. These outcomes are highly dependent on the
characterization criteria for each impact, such as severity, repetitive injury, and even location of
insult. Nonetheless, the various secondary injuries associated with all varieties of TBI has been
demonstrated to give rise to a multitude of neuropathological conditions, some of which include
seizures, neurodegenerative diseases, elevations in intracranial pressure, neuroendocrine
dysfunction, and psychiatric illness (Bramlett & Dietrich, 2015). Many of the pathological
conditions associated with TBI stem from the cascades of cellular and molecular changes that
occur at various timepoints after injury. It is imperative to better understand the acute, subacute,
and chronic molecular sequelae consequential to TBI, as this understanding may aid research
developments of novel targeted therapies aimed at eliminating the unforgiving behavioral
consequences associated with various forms of TBI.
Apoptosis
One of the most acute detrimental pathways associated with TBI is apoptosis, a type of
programmed cell death in which the cell initiates a cascade of molecular events that lead to its

15
own termination. Over the past few decades, the field of apoptosis had branched into several
specified niches of programmed cellular death that differ based on factors such as initial
apoptotic signal, disruption of specific organelles, and even the release of cellular contents after
apoptosis. Nonetheless, the general process of classical apoptosis initiates from either an external
death receptor pathway or an internal apoptotic signal. The external pathway is initiated by the
binding of a deleterious ligand, such as tumor necrosis factor-alpha, to its corresponding
receptor. Proper binding will initiate the autoproteolytic processing and activation of caspase-8
(CASP8), a proteolytic cleavage enzyme responsible for the activate other downstream caspases,
as well as the activation of a B-cell lymphoma 2 (Bcl-2) protein known as truncated Bcl-2
homology 3 (BH3) interacting-domain death agonist, which is implicated in the internal
apoptotic pathway. The internal pathway, also known as the mitochondrial pathway, is triggered
via intracellular dysfunction (e.g., elevated levels of misfolded protein, improper pH, and other
forms of impaired cellular homeostasis) which results in the activation of BH3-only domain
proteins. BH3-only proteins are members of the B-cell lymphoma 2 family and are considered
essential initiators of apoptosis that function to activate Bcl-2-associated X protein, a protein
known to form pores in the outer mitochondrial membrane. The untruncated BH3 interactingdomain death agonist, the inactive precursor of truncated BH3 interacting-domain death agonist,
is considered a BH3-only protein, and thus contributes to the activation of Bcl-2-associated X
protein. Once Bcl-2-associated X protein is activated, it will oligomerize and embed into the
mitochondrial membrane to subsequently releases cytochrome c which is known to initiate the
activation of downstream caspases. One of the final caspases in this pathway is caspase-3
(CASP3), which is known as an executioner caspase due to its low proteolytic specificity,
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thereby allowing CASP3 to cleave a wide range of proteins in the cells and finalize cellular
death. Given that the molecular mechanisms of apoptosis are composed of several
intercommunicating proteins, literature review has identified CASP8 as a general marker for
extrinsic apoptosis and CASP3 as a general marker for apoptosis (Fricker et al., 2018).
Necroptosis
Similar to apoptosis, necroptosis is also a common mechanism of programmed cell death
found at acute timepoints after injury. Necroptosis is initiated by external signals associated with
disease, injury, and blood supply failure, and results in the swelling of cellular organelles, plasma
membrane rupture, and the eventual lysis of the cell. Rupturing of the cell differentiates
necroptosis from apoptosis, due to the detrimental nature of releasing intracellular contents into
the surrounding cellular environment (Yu et al., 2021). Once necroptosis is initiated via a
necroptosis-inducing external stimulus, it leads to the activation of receptor-interacting
serine/threonine-protein kinase 1 (RIPK1). RIPK1 is known to phosphorylate another
serine/threonine kinase known as receptor-interacting serine/threonine-protein kinase 3, which,
once phosphorylated, drives the phosphorylation of a pseudo kinase known as mixed lineage
kinase domain-like that is known to oligomerize into a structure termed the necrosome. The
activated necrosome will then be processed to phosphorylate more mixed lineage kinase domainlike protein at the plasma membrane and lead to cell rupture and necrosis (Fricker et al., 2018).
Key mediators of necroptosis are RIPK1, receptor-interacting serine/threonine-protein kinase 3,
and mixed lineage kinase domain-like protein.
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Pyroptosis
Pyroptosis is an inflammatory mediated form of programmed cellular death that is
initialed via inflammatory cytokines and proceeds via the formation of a structure termed the
inflammasome. Inflammatory cytokines and various interleukins commence pyroptosis via the
cleavage of pro-caspase-1 into active caspase-1 within the inflammasome. The inflammasome is
a cytosolic protein complex composed of nucleotide-binding oligomerization domain proteins,
apoptosis-associated speck-like protein containing a C-terminal caspase recruitment domain
adaptor proteins, and pro-caspase-1, which, when activated, released active caspase-1 to cleave
pro-inflammatory cytokines and the protein gasdermin D (GSDMD). Similarly, to Bcl-2associated X protein in the intrinsic apoptotic pathway, cleaved GSDMD will create direct pores
in the plasma membrane and facilitate the release of inflammatory signals into the surrounding
cellular microenvironment (Fricker et al., 2018). Given that pyroptosis releases cellular contents,
it is considered a form of regulated necrosis. Key mediators for this pyroptosis are activated
caspase-1 and GSDMD.
Oxidative Stress
Many of the initial molecular sequelae associated with TBI are related to cellular death
and consequential changes in the cellular microenvironment. Oxidative stress, defined by the
imbalance between oxidant and antioxidant agents within the cell, is a precursor to cellular death
via TBI and has the potential to contribute to sustained neural death and dysfunction after injury
(Ma, M. W. et al., 2018). The formation of oxidative stress is attributed to the generation of
unstable molecules that contain at least one or more unpaired valence electrons, known as free
radicals. These highly reactive molecules and are typically categorized as reactive oxygen
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species (ROS) or reactive nitrogen species (RNS), based on their derived molecular structure.
ROS include superoxides, hydrogen peroxide, hydroxyls, peroxyl, and alkoxyl while RNS
include nitric oxide and nitrogen dioxide (Liguori et al., 2018). Both ROS and RNS are derived
from byproducts of cellular metabolism, and levels of oxidative stress are mediated through
enzymes that procure these reactive byproducts as well as antioxidant enzymes that reduce them
to more stable molecules such as water and oxygen. Numerous studies that analyze biochemical
markers related to TBI have indicated that there is a general increase in ROS and RNS along
with a general decrease in antioxidant defense enzymes such as glutathione peroxidase, catalase,
and superoxide dismutase (Rodríguez-Rodríguez et al., 2014). An increase in reactive ROS and
RNS, along with a decrease in antioxidant defense enzymes, would give rise to a shift in
oxidative homeostasis in the cell, which is known to be directly related to the pathogenesis of
TBI (Rodríguez-Rodríguez et al., 2014). Published findings have demonstrated that deletion of
nicotinamide adenine dinucleotide oxidase 4 (NOX4), a constitutively active transmembrane
oxidoreductase involved in the production of hydrogen peroxide, resulted in a reduced number of
apoptotic and degenerating cells after TBI, as well as smaller lesion volumed compared to
untreated mice (Ma, M. W. et al., 2018). These findings indicate that NOX4 may be utilized as
an indicator of oxidative stress in an experimental model of rmTBI.
Protein Folding
Analogous to the microenvironmental alterations in oxidative stress that surround TBI, a
lack of cellular homeostasis after brain injury may impact routine molecular processes such as
protein folding. Protein folding is a highly sensitive and critically important molecular
mechanism that may be influenced by external factors including temperature, pH, limitations in
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space, and even magnetic fields. Given that all proteins must undergo proper protein folding to
assume a functional 3-dimensional conformation, a deviation in the microenvironment associated
with TBI may drastically impact normal protein folding within the cell. Chaperones, such as
those of the heat shock protein family, are functionally related groups of proteins known to assist
protein folding, and the need for chaperones within the cell becomes elevated in times of cellular
distress. Within the field of TBI, research has demonstrated that animals who receive TBI show
significant functional improvement when treated with drugs that specifically increase levels of
heat shock protein 70 and heat shock protein 110 (Kim, J. Y. et al., 2013; Eroglu et al., 2014).
Concordantly, heat shock protein family A member 1B (HSPA1B), a member of the heat shock
protein 70 family, is considered an inducible chaperone protein due to its biological function to
mitigate improper protein folding in times of cellular stress (Daugaard et al., 2007).
Neuroregeneration
Neuroregeneration is often considered a chronic process in TBI and is thought to occur at
later timepoints after injury. While adult neurogenesis is much more prominent in the peripheral
nervous system compared to the central nervous system, specific neurotrophins, such as brainderived neurotrophic factor (BDNF), glia-derived nerve factor, and insulin-like growth factor,
have been shown to contribute to neuronal survival (Keefe et al., 2017). Specifically, BDNF
binding to its corresponding receptor, tropomyosin-receptor-kinase B has been shown to initiate
several intracellular signaling cascades, some of which inhibit the pro-apoptotic Bcl-2-associated
agonist of cell death protein and, as a result, promote the expression other anti-apoptotic proteins
in the Bcl-2 family (Yoshii & Constantine‐Paton, 2010). The therapeutic potential of BDNF has
been established in many neuropathological conditions and offers promising potential in the
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context of TBI (Wurzelmann et al., 2017). Since BDNF is too large to cross the blood-brain
barrier, studies that have focused on the indirect delivery of BDNF to the brain have observed
functional recovery using rodent weight drop models of TBI and elevated levels of BDNF in
animals who demonstrated improved neurological outcomes (Khalin et al., 2016). More recent
work that focused on the transplantation of exosomes containing BDNF into the brain after TBI
has also demonstrated functional recovery and promotion of neurogenesis (Xu, H. et al., 2020).
These findings suggest that BDNF levels may be utilized as a prominent indicator of
neuroregeneration following rmTBI.
Testosterone Therapy in mTBI
The ability of testosterone to be produced de novo in the brain highlights its evolutionary
necessity for normal healthy brain function. Testosterone, and its metabolic androgenic
byproducts, act via two independent genomic and nongenomic pathways. The classical genomic
pathways are initiated through the activation of androgen receptor (AR) binding to specific
genomic sequence motifs termed androgen response elements. The androgen response elements
are present in promoters and enhancers of genes targeted by the AR and thereby lead to the broad
regulation of mRNA transcription and subsequent protein synthesis. Classical genomic AR
activation pathways are regarded as slow in nature due to the dependency of androgens to
translocate into the nucleus (Bianchi et al., 2020). On the contrary, nongenomic pathways give
rise to responses within seconds to minutes because they do not require nuclear translocation
(Foradori et al., 2007). Nongenomic pathways, also termed non-canonical pathways, are a
relatively novel field of steroid-mediated activation, and function through the activation of the
membrane androgen receptor (mAR). Several mARs are classified as G-protein coupled
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receptors and have been shown to initiate a cascade of signaling events upon activation in order
to modulate transcription and translation.
Testosterone treatment has been shown to have a variety of neuroprotective effects in
various conditions of neuropathological disease. In a phase II clinical trial, testosterone treatment
reversed gray matter atrophy in the thalamus, and basal ganglia, associated with multiple
sclerosis (Kurth et al., 2014). In an animal model of spinal cord injury, testosterone treatment
prevented decreases in dendritic length in motoneurons, and reduced atrophy in muscle
morphology (Byers et al., 2012). In animal models of Alzheimer’s Disease, testosterone, and its
metabolite dihydrotestosterone, were shown to reduce beta-amyloid production, improve
cognitive function (McAllister et al., 2010), and protect against the acceleration of
neurodegenerative pathology (Rosario et al., 2006). Additionally, testosterone has been shown to
reduce neuroinflammation, inhibit oxidative stress, and promote neuronal survival (Yang et al.,
2020; Wang, L. et al., 2019; Spritzer & Galea, 2007). Collectively, these data indicate that
testosterone treatment has therapeutic benefits across several varying neuropathological
conditions, which warrants the potential for testosterone to have neurotherapeutic effects in TBI.
Only a small number of studies have examined the neurotherapeutic value of testosterone
in the context of TBI (Carteri et al., 2019; Ripley et al., 2020). Given that disruptions in
neuroendocrine function are one of the many physical symptoms associated with TBI,
hypogonadism, a reduction in levels of gonadal steroids, is a common phenomenon observed in
TBI patients. Post-TBI hypogonadism prompted investigations into gonadal steroid replacement
therapy after injury (Wagner et al., 2010; Young et al., 2007), and subsequently gave rise to the
potential therapeutic value of testosterone treatment in TBI. Nonetheless, many of these
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investigations only examine testosterone in hypogonadal animal models. The Foecking Lab has
demonstrated that delayed systemic testosterone treatment in a rmTBI paradigm improved
vestibular behavioral outcomes, as well as damped neuronal death associated with brain injury
(Segismundo, 2019). While the effect of testosterone is clearly beneficial in this model, the
specific molecular underpinnings of delayed testosterone treatment in the context of rmTBI
remain widely unexplored.
Treatment Strategies for Chronic Vestibular Dysfunction after mTBI
Currently, individuals suffering from vestibular impairments do not have many
therapeutic options. Pharmacologically, there are no drugs available targeting the root cause of
vestibular dysfunction after mTBI. Although medications that target symptoms such as dizziness
or nausea are commercially available, targeting symptoms rather than root problems can force
individuals to live with difficult side effects and create a strong drug reliance. The only direct
treatment is a form of therapy known as vestibular rehabilitation therapy. This specific type of
treatment consists of multiple targeted vestibular physical therapy sessions per week, is timeintensive, highly expensive, and offers unpromising results for relieving vestibular impairment
(Marcus et al., 2019; Alsalaheen et al., 2010; Murray et al., 2017). Given that there are currently
no pharmaceutical treatment strategies targeted at treating the root of vestibular impairments
following rmTBI, there is an immense need to investigate the molecular underpinnings
associated with rmTBI at clinically relatable timepoints.

CHAPTER 3
RESEARCH DESIGN
Rationale for Study Design
The purpose of this thesis is to investigate the molecular underpinning of delayed
testosterone treatment in the vestibular nucleus after rmTBI. Given that mild TBI is the most
frequent severity of TBI, this study utilizes an animal model for mTBI. Males are twice as likely
to sustain TBI compared to females, so this research was exclusively performed on male rats. In
order to clinically mimic mTBI, a closed-head repetitive mild injury was induced using a
controlled cortical impactor to deliver accurate and repeatable insults. It is known that
individuals that sustain repetitive TBIs increase their susceptibility to worsened outcomes after
each insult; however, little is known about the neuropathology specific to rmTBI therefore
rmTBI was the chosen paradigm for this research study.
Mild TBI is associated with a host of neurobehavioral symptoms, with vestibular
impairment being a hallmark complaint after initial impact. Analogous to all mTBI symptoms,
vestibular deficits typically diminish with time; however, in cases where vestibular impairments
do not attenuate, these impairments can impact day-to-day activities and severely reduce quality
of life. For this reason, this study exclusively focuses on the vestibular nucleus, a region
responsible for maintaining vestibular function. Currently, the majority of TBI research
investigates delivering treatments and examining molecular alterations at acute time points after
injury, such as hours or days after impact. Nonetheless, these timepoints do not reflect the
23
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clinical guidelines associated with mTBI which instruct patients to self-monitor their recovery
before seeking additional medical assistance if symptoms do not resolve with time. Under these
guidelines, patients who do not recover with time are likely to present lingering vestibular
impairments weeks to months after initial insult. Therefore, it is imperative to examine if chronic
molecular dysfunction associated with rmTBI can be identified at extended timepoints after
injury as this will likely be when patients receive treatment or therapy for a TBI of mild severity.
Past findings in the Foecking Laboratory have demonstrated that a closed-head rmTBI
rodent model resulted in functional vestibular impairment that mimics the prolonged vestibular
deficits found in a subset of rmTBI patients. Additionally, rats with sustained vestibular
deficiencies exhibited neuronal loss in both the ipsilateral and contralateral vestibular nuclei. The
administration of delayed systemic testosterone treatment improved vestibular behavioral
measurements and ameliorated neuronal cell loss in the vestibular nucleus (Foecking et al.,
2022). The loss of neurons in the vestibular nucleus at chronic timepoints after injury may be the
result of the prolonged dysregulation in cellular mechanisms that preclude cellular death. It is
known that complex biochemical cascades that govern the homeostasis of free radicals,
apoptosis, protein folding, and regeneration are all involved in the secondary injury after mTBI.
Several of these mechanisms are also affected by testosterone. Nonetheless, many of the
mechanistic alterations from testosterone treatment are only investigated at acute timepoints after
insult. This study aims to explore the molecular alterations associated with rmTBI in the
vestibular nucleus and investigate the mechanisms by which testosterone is acting as a
neurotherapeutic after injury.
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Study Design
Eight-week-old male Long-Evans Hooded rats received five mTBI over the course of
eight days with each impact spaced 48 hours apart. Rats were divided into three categories:
sham, rmTBI, and rmTBI + T. Sham rats did not receive an insult and acted as a control for
injury, rmTBI rats received an insult via a metal piston through a CCI device, and rmTBI + T
rats received an insult while also receiving a delayed systemic testosterone treatment, in the form
of an implantable capsule, at 35-DPI. Regardless of group, all rats received equal doses of
anesthesia, and rats that sustained mTBIs were sedated prior to impact. Sham rats underwent the
same anesthesia protocol as rmTBI rats but did not receive an impact. The rats were then given
time to recover for 35 days after the final rmTBI. 35-DPI was chosen as a clinically relevant
timepoint to represent when patients may seek or receive treatment after injury. Animals from
each group were euthanized sequentially at 35, 37, 42, and 63 DPI in order to represent 0, 2, 7,
and 28 days after the delayed testosterone treatment timepoint on 35 DPI. At each euthanasia
timepoint, brains were harvested, and vestibular nuclei were removed, homogenized, and stored
for future molecular analysis. Brain homogenates were then extracted and purified for mRNA
analysis via RT-qPCR and protein analysis via western blotting.
Chronic molecular alterations associated with rmTBI are reported to impact apoptosis,
oxidative stress, protein folding, and regeneration. Given that these pathways incorporate several
key proteins, the following markers were chosen to represent potential pathway-specific
molecular alterations associated with rmTBI and T treatment: BDNF, HSPA1B, NOX4, CASP3,
CASP8, GSDMD, and RIPK1. The proposed study helps uncover the mechanistic molecular
changes associated with rmTBI and testosterone treatment in the vestibular nucleus at clinically
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translational timepoints after injury. In doing so, this thesis is the first of its kind to specifically
investigate the long-term molecular changes associated with rmTBI in the vestibular nucleus to
better understand how testosterone treatment attenuates the chronic vestibular deficits often
observed in patients suffering from rmTBI. An experimental timeline of the research design is
shown in Fig. 1.

48 hrs

Figure 1: Experimental Timeline. Animals were split into 3 groups: sham, rmTBI, and rmTBI
+ T. Sham animals acted as controls and did not receive rmTBI, while rmTBI animals were
subject to five total mTBIs spaced 48 hours apart. After the final mTBI, days are referenced as
DPI. On 35 DPI, half the TBI animals were treated with systemic testosterone via implanted
capsules. Subsequently, animals from all groups were euthanized (brain symbol) in cohorts either
0, 2, 7, or 28 days after 35 DPI, represented as 35, 37, 42, and 63 DPI, respectively.

CHAPTER 4
METHODOLOGY
Power Analysis
Required sample size for this study was calculated by conducting an a priori power
analysis using an alpha of 0.05, power of 0.80, and effect size of 0.40. An alpha error probability
of 0.05 and a power of 0.80 are standard across scientific research, and an effect size of 0.40 was
chosen based on preliminary results and literature review. These input criteria yielded a total
sample size requirement of 64 animals. An attrition rate of ~10% was applied to account for
unexpected death and potential sample loss to yield a required total sample size of 72 animals
which was divided across three groups and four timepoints to yield a sample size of six per
timepoint for each group. This sample size is consistent with published literature analyzing
delayed treatments in rmTBI animal models.
Animals
Eight-week-old male Long Evans Hooded rats were obtained from Envigo Laboratories
and housed in groups of three at the Edward Hines Jr. Veterans Administration Hospital
Veterinary Medical Unit. The animals were held in temperature and humidity-controlled
chambers, exposed to a 12:12 light/dark cycle and had access to enrichment, standard chow, and
water ad libitum. Prior to any experimentation, all rats were given approximately one week for
acclimation, in which they were handled on a regular basis. Once rats plateaued in size (~300g)
they were housed in groups of two to adhere to sizing constraints for the remainder of the study.
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All procedures were approved by the Institutional Animal Care and Use Committee of Edward
Hines Jr. Veterans Administration.
Closed-Head Controlled Cortical Impact
Repetitive mild TBI was induced in male rats with a close-headed CCI using a Leica
Impact One Stereotaxic impactor device (Leica Biosystems). Rats were placed in an induction
chamber (VetEquip) and anesthetized using 3% isoflurane with an oxygen flow rate of 1 L/min
for approximately five minutes until rendered unconscious. Once insentient, the right side of the
skull was shaved to expose the area of impact. Subsequently, the rats were placed prone on a 5
cm thick foam bed mounted to an acrylic frame and administered anesthesia via nosecone. The
acrylic frame consisted of a base and side piece angled 11° from a vertical plane. The side piece
provided the rat body with stabilization throughout the mTBI, while allowing for free range of
head movement during impact, thereby closely modeling the clinical etiology of mTBI seen in
patients.
The CCI device delivered mTBI at an angle of 20° from a vertical in order to position the
flat impactor tip perpendicularly to the skull of each animal before insult. The steel impactor tip
has a diameter of 5 mm and was carefully positioned over the sensorimotor cortex before
delivering each impact. Sensorimotor cortices are estimated using anatomical landmarks in
reference to bregma (0.5 mm anterior and 4.0 mm lateral), which correspond to the halfway point
between the lateral edge of the right eye and the medial tip of the right ear. The moment before
the impactor tip was fired, the nosecone was removed, and the researcher stabilized the rat body,
but not the head, by gently placing a hand over the animal’s body. The impactor tip then
delivered each mTBI by traveling at 6.5 m/s, at a height of 10 mm from the surface of the skin,
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and at a dwell time of 300 msec. The parameters are well-established to cause TBI of mild
severity in rat and have been replicated in the past by our laboratory.
After each impact, animals were inspected for laceration from the impactor tip and
palpated for skull fracture. Subsequently, rats were weighed and placed in an individual cage
while recovering from anesthesia. Once rats regained sternal recumbency, they were transferred
back to their home cage and returned to the veterinary medical unit. This procedure was repeated
for a total of five impacts, spaced 48 hours apart to model rmTBI. Sham rats received identical
treatment apart from insult. Given that this is a closed-head rmTBI model, each mTBI was
performed by one singular researcher to minimize alterations in impact and positioning and
thereby maintain replicability between repetitive insults across all animals.
Brain Tissue Collection and Processing
Rats from each experimental group were anesthetized with isoflurane, decapitated, and
brains were harvested. A rat brain atlas (Paxinos & Watson, 2007) was used to locate the region
containing the vestibular nuclei, and brains were put into a brain matrix to create a 3 mm thick
coronal section from the rostral medulla to the caudal pons containing both the ipsilateral and
contralateral vestibular nuclei. Then 1.5 mm concentric tissue punches were performed laterally
of the 4th ventricle to isolate both the ipsilateral and contralateral nuclei. The vestibular nuclei
were then bead homogenized in TRIzol Reagent (Thermo Fisher Scientific) and stored at -80 °C
for future processing.
Reverse Transcription Quantitative Real-Time Polymerase Chain Reaction
Total RNA was extracted from each brain homogenate using TRIzol Reagent per
protocol instructions and subsequently purified using an ethanol purification before being tested
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for purity and concentration using a NanoDrop 2000 (Thermo Fisher Scientific). Purified RNA
(100 ng) was then reverse transcribed into cDNA using the SuperScript IV VILO Master Mix
with ezDNase (Thermo Fisher Scientific) according to manufacturer instructions. A total of six
genes of interest were chosen for analysis to represent processes that may be dysfunctional at
extended timepoints after rmTBI (≥ 35 DPI). Genes are listed below in Table 1.
Table 1: Genes of Interest. Genes used as representative markers for pathways which could be
altered by rmTBI or testosterone treatment at extended timepoints after injury.
Gene Name

Abbreviation

Involved Pathway

Brain Derived Neurotrophic Factor

Bdnf

Neuroregeneration

NADPH Oxidase 4

Nox4

Oxidative Stress

Caspase-8

Casp8

Extrinsic Apoptosis

Heat Shock Protein Family A Member B

Hspa1b

Protein Misfolding

Gasdermin D

Gsdmd

Pyroptosis

Receptor Interacting Protein Kinase 1

Ripk1

Necroptosis

All rat-specific primers used to amplify the cDNA for the genes of interest were
proprietarily premade, experimentally validated, and purchased through Bio-Rad Laboratories.
Transcriptional analysis was performed using RT-qPCR in 20 µl reaction volumes using 10 ng of
cDNA, 1 µl of forward and reverse primer, and 10 µl of SsoAdvanced™ Universal SYBR Green
Supermix (BioRad Laboratories) for each sample in technical triplicates on a 96 well plate and
each target gene was processed. Thermal cycling was carried out on the CFX96 Touch RealTime PCR detection system (BioRad Laboratories) and analyzed using CFX Manager software
(BioRad Laboratories). Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as the

housekeeping gene to determine relative target gene expression using the 2

-ΔΔCt

31
method (Livak &

Schmittgen, 2001). Statistical analysis was performed on ∆∆Ct values, using sham as control
when analyzing the effect of injury and rmTBI as control when analyzing the effect of treatment.
Graphs represent mean relative quantity (RQ) ± RQ max and min, derived from the standard
error of the mean (SEM).
Western Blotting
Total protein was extracted and purified from each homogenate using the TRIzol Reagent
protocol according to manufacturer’s instructions, along with a heating and vertexing to achieve
complete suspension of protein (Likhite & Warawdekar, 2011). The Lowry method was
performed on each sample to obtain protein concentrations using commercially available DC
Protein Assay reagents (BioRad Laboratories). Samples were then diluted to equal concentration
before further protein analysis via western blot.
Due to the nature of diffuse secondary injury and limited sample quantity, contralateral
and ipsilateral total protein samples were combined. Samples containing 7 µg of total protein
were prepared using Bolt LDS Sample Buffer (Thermo Fisher Scientific) and Bolt Reducing
Agent (Thermo Fisher Scientific). Prepared samples were loaded into Bolt 4-12% Bis-Tris Plus
Mini Gels (Thermo Fisher Scientific), and gel electrophoresis was performed for 40 minutes at a
constant 200 V in a Mini Gel Tank using Bolt MES SDS Running Buffer (Thermo Fisher
Scientific). Gels were subsequently transferred to a membrane using an iBlot 2 Gel Transfer
Device (Thermo Fisher Scientific) using a custom protocol (20V for 12 min). Membrane transfer
was assessed using Ponceau S staining solution (Research Products International) before protein
detection using an iBind Western System (Thermo Fisher Scientific).
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The following primary antibodies were used: rabbit anti-HSPA1B (1:500; PA5-28369,
Thermo Fisher Scientific), rabbit anti-NOX4 (1:500; ab133303, Abcam), rabbit anti-CASP3
(1:500; 9662S, Cell Signaling Technology), rabbit anti-GSDMD (1:500; 20770-1-AP, Thermo
Fisher Scientific), and rabbit anti-β-actin (1:1000; 4970S, Cell Signaling Technology) as control.
Primary antibodies were probed using an anti-rabbit HRP-conjugated secondary antibody (1:400;
7074S, Cell Signaling Technology) and detected using Immobilion Forte Western HRP Substrate
(Millipore Sigma) when probing for β-actin or SuperSignal West Femto Maximum Sensitivity
Substrate (Thermo Fisher Scientific) when probing for all other proteins of interest. All images
were acquired using Azure 600 Imaging System (Azure Biosystems) and analyzed using Image
Lab software (BioRad Laboratories).
Statistical Analysis
All statistical analyses were performed using GraphPad Prism Version 9.2.0. and p ≤ 0.05
was considered the threshold for statistical significance. Outliers were removed using the outlier
removal function in Prism (ROUT, Q = 1%), and data were assessed for normality before
performing statistical analysis. Two-way ANOVA was carried out to assess variance between
timepoints and groups, one-way ANOVA to assess variance among a specific group at individual
timepoints, and unpaired t-test to assess variance for specific factors, such as injury (sham vs.
rmTBI) or treatment (rmTBI vs. rmTBI + T), at individual timepoints, or collectively across
combined timepoints. Statistical significance for p ≤ 0.10, p ≤ 0.05, and p ≤ 0.01 are represented
as [*], *, and **, respectively.

CHAPTER 5
SPECIFIC AIM 1
Aim 1: Experimental Question 1.1
Does a 5-hit rmTBI model produce mRNA alterations in apoptotic, cellular stress, and
regenerative pathways in the vestibular nucleus at subacute timepoints after rmTBI?
Rationale
Rodent models of TBI have demonstrated that diffuse secondary injury after insult has
been shown to induce changes in mRNA expression at early timepoints (0-7 days) after injury
(Wu et al., 2021; Salberg et al., 2018; Shaheen et al., 2021). These expression patterns correlate
to behavioral deficits and have been shown to diminish with factors such as time and number of
repetitive insults (Witcher et al., 2021; Huynh et al., 2020). Analogous to all rmTBI symptoms,
vestibular deficits typically diminish with time; however, in cases where vestibular impairments
do not attenuate, these impairments can impact day-to-day activities and severely reduce quality
of life. From a clinical perspective, acute timepoints after injury do not reflect the week-to-month
timeframe at which patients with lingering vestibular impairment typically wait before seeking
appropriate medical attention. Thus, it is critical to examine if transcriptional changes associated
with rmTBI can be detected in the vestibular nucleus at subacute timepoints in this model.
Past findings in the Foecking Laboratory have demonstrated that a rmTBI animal model
resulted in vestibular deficiencies measured via a robust behavioral vestibular battery
(Segismundo, 2019). These behavioral impairments mimic the prolonged vestibular deficits
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found in a subset of rmTBI patients and provide a unique paradigm to study the molecular
changes associated with injury at extended timepoints. Additionally, it has been demonstrated
that animals with sustained vestibular impairments showed neuronal loss in both the ipsilateral
and contralateral vestibular nuclei, likely due to the diffuse secondary nature of injury (Foecking
et al., 2022). The loss of neurons in the vestibular nucleus at chronic timepoints after injury may
be the result of the prolonged dysregulation in cellular mechanisms that preclude cell death. It is
known that complex processes that govern the homeostasis of free radicals, apoptosis, protein
folding, and regeneration are all involved in the secondary injury after mTBI (Ladak et al.,
2019); however, many of these mechanisms are only investigated at acute and early subacute
timepoints after insult. The purpose of this aim is to explore if rmTBI can lead to sustained
disruption in mRNA markers associated with brain injury.
Chronic molecular alterations associated with rmTBI are reported to impact apoptosis,
oxidative stress, protein folding, and regeneration (Bramlett & Dietrich, 2015; Shaheen et al.,
2021; Eroglu et al., 2014; Xu, H. et al., 2020). Given that all these pathways incorporate several
key mediators, the following genes were chosen as representative markers for potential sustained
dysfunction after rmTBI: Casp8, Rip1k, Gsdmd, Nox4, Hspa1b, and Bdnf. This study will help
uncover the transcriptional changes associated with rmTBI in the vestibular nucleus at clinically
translational timepoints after injury. In doing so, this thesis will be the first of its kind to
specifically investigate long-term mRNA expression patterns associated with a closed-head 5-hit
rmTBI in the vestibular nucleus. The identification of mRNA markers associated with injury will
contribute to the future development of targeted vestibular treatments for rmTBI.
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Results
mRNA expression after rmTBI at 35, 37, 42, and 63 DPI. In order to investigate
mRNA expression patterns after 5-hit rmTBI at subacute timepoints after injury, RT-qPCR
analysis was performed on the ipsilateral vestibular nucleus for various genes of interest 35, 37,
42, and 62 DPI (Fig.2). Sample size for sham and rmTBI groups was 4-6 per group at each
timepoint, with the exception of the rmTBI animals at 35 DPI, N = 12. Unpaired two-tailed ttests were performed at each timepoint to analyze transcriptional changes between sham and
rmTBI rats for each gene of interest. A statistically significant elevation in Hspa1b was observed
in rmTBI rats (1.80 +0.29/-0.25; p = 0.0351) when compared to uninjured sham at 42 DPI (Fig.
2C). Additionally, strong upregulations in rmTBI animals were also detected for Nox4 (1.77
+0.32/-0.26; p = 0.517) and Gsdmd (1.46 +0.12/-0.11; p = 0.0567) at 42 DPI (Fig. 2C). A
prominent pattern was noticed in rmTBI animals for Ripk1 (1.29 +0.08/-0.08; p = 0.0769) at the
latest 63 DPI (Fig. 2D) when compared to uninjured sham. Interestingly, the trends in gene
expression for rmTBI animals were only observed at the furthest timepoints after injury and
seem to be most specific to animals at 42 DPI. These data reveal that transcriptional
upregulations in markers for detrimental pathways are still detectable in the vestibular nucleus
even at 42 and 63 DPI.
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Figure 2: rmTBI Increases the Expression of Genes Involved in Protein Misfolding,
Oxidative Stress, and Pyroptosis at 42 DPI. Gene expression relative to sham for six genes of
interest in the ipsilateral vestibular nucleus at various extended timepoints after injury. (A) 35
DPI, (B) 37 DPI, (C) 42 DPI, (D) 63 DPI. All genes were normalized to Gapdh and sham was
used as the control group. Error bars presented as mean RQ ± RQ max & min. N = 4-6 per group
except for 35 DPI rmTBI, N = 12. [*] p ≤ 0.1, * p ≤ 0.05.
mRNA expression after rmTBI at combined timepoints following injury. In order to
determine if the expression patterns from Fig. 2 would be sustained across all timepoints, a twoway ANOVA was performed for each gene to analyze the effect of injury (levels = 2 (sham &
TBI) and time (levels = 4 (35, 37, 42, and 63 DPI)). The preliminary ANOVA for each gene
revealed no effect of time, and no interaction between time and injury, so all timepoints were
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combined to run an unpaired two-tailed t-test to exclusively analyze the effect of rmTBI (Fig. 3).
Combined sample sizes yielded 21-26 animals per group. Although trends were present, no
significant differences were found between sham and rmTBI groups upon the exclusion of time.
Gsdmd, the representative marker for pyroptosis, was the closest gene to observe a notable
difference between sham and rmTBI irrespective of time (1.17 +0.07/-0.07; p = 0.0673), (Fig.
3E).

Figure 3: rmTBI Increases the Expression of Gasdermin D at Combined Timepoints After
Injury. Gene expression relative to sham for six genes in the ipsilateral vestibular nucleus
combined at all timepoints (35, 37, 42, and 63 DPI) following injury. (A) Bdnf, (B) Hspa1b, (C)
Nox4, (D) Casp8, (E) Gsdmd, and (F) Ripk1. All genes normalized to Gapdh. Error bars
represent mean RQ ± RQ max & min. N = 21-26 per group. [*] p ≤ 0.1.
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Aim 1: Experimental Question 1.2
What effect does delayed systemic testosterone treatment have on mRNA expression for
apoptotic, cellular stress, and regenerative pathways in the vestibular nucleus after 5-hit rmTBI?
Rationale
The neuroprotective effects of testosterone, an endogenous androgen, are well
documented. The biochemical properties that allow testosterone to permeate the blood-brain
barrier, along with its ability to be synthesized in the brain via neurosteroidogenesis, give it
potential as a therapeutic compound after brain injury. The unique biochemical properties of
testosterone allow for it to act traditionally via androgen receptors or become metabolized into
estrogen and act through estrogenic receptors. Both androgen receptors and estrogen receptors
are found abundantly in the brain, specifically in the vestibular nucleus (Grassi et al., 2013). This
aim proposes that testosterone may have neurotherapeutic value for individuals suffering from
chronic vestibular deficiencies related to rmTBI.
After an individual suffers an mTBI, clinical care guidelines instruct the individual to rest
and recover for a period of two weeks before returning for a follow-up. Given that this is the
standard of care, lingering deficits, such as vestibular problems, often take weeks to months
before they can be accurately diagnosed. This extended timeframe assumes that patients will not
receive a therapeutic agent directly after mTBI, but rather several weeks or months after injury.
The realistic clinical timeframe is in stark contrast with the overwhelming mass of academic
research that investigates the efficiency of therapeutic compounds for rmTBI, merely minutes,
hours, and days after injury (Shaheen et al., 2021; Rehman et al., 2019; Song et al., 2016;
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Maynard et al., 2019). For this reason, this aim utilizes a delayed systemic testosterone paradigm
rather than traditional administration shortly after the onset of injury.
Previous work in the Foecking Lab has demonstrated that delayed testosterone after
rmTBI effectively ameliorated vestibular behavioral deficits associated with injury while also
improving neuronal survival in the vestibular nucleus (Foecking et al., 2022). However, the
specific molecular underpinnings of how testosterone acts as a neurotherapeutic at extended
timepoints after rmTBI remain largely unexplored. In order to address this gap in knowledge,
this study analyzed the mRNA expression patterns associated with delayed testosterone
treatment in the vestibular nucleus at extended timepoints after rmTBI.
Results
mRNA expression after delayed systemic testosterone treatment at 37, 42, and 63
DPI. In order to investigate the time-dependent relative gene expression associated with
testosterone treatment after rmTBI, RT-qPCR analysis was performed on the ipsilateral
vestibular nuclei of rmTBI untreated and rmTBI testosterone-treated rats for various genes of
interest 0, 2, 7, and 28 days after testosterone treatment on 35 DPI, corresponding to 35, 37, 42,
and 63 DPI, respectively (Fig. 4). The 35 DPI timepoint was excluded from the analysis because
rmTBI rats were subdivided into treatment groups at this timepoint. All rats euthanized 35 DPI
were pooled into the rmTBI group as euthanasia took place immediately after treatment, and
thereby preventing a systemic testosterone capsule from initiating any effect in the brain. An
unpaired two-tailed t-test was performed for each gene at each timepoint to analyze the relative
mRNA expression patterns associated with delayed testosterone treatment as compared to
untreated rmTBI animals. Sample sizes were 4-6 per group. While there were many trends in this
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data, only animals euthanized 2 days after testosterone treatment (37 DPI) were shown to have
significant decreases in expression for Casp8 (0.67 +0.04/-0.04; p = 0.0064), Gsdmd (0.69
+0.10/-0.08; p = 0.0388), and Bdnf (0.61 + 0.10/-0.09; p = 0.0470) when compared to the
untreated rmTBI animals (Fig. 4A). Similarly, relative expression levels were reduced for
Hspa1b (0.65 +0.15/-0.12; p = 0.0895) and Ripk1 (0.73 +0.10/-0.09; p = 0.0646) at 37 DPI (Fig.
4A), and Casp8 (0.77 +0.07/-0.05; p = 0.0675) and Ripk1 (0.76 +0.08/-0.07; p = 0.0728) at 63
DPI (Fig. 4C); however, this decrease did not reach statistical significance when compared to
rmTBI animals that did not receive testosterone treatment.
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Figure 4: Delayed Testosterone Reduces mRNA Expression of Upregulated Deleterious
Genes at Acute and Extended Timepoints After rmTBI. Gene expression relative to rmTBI
for six genes of interest in the ipsilateral vestibular nucleus following delayed testosterone
treatment. 37, 42, and 63 DPI represent 2,7, and 28 days after testosterone treatment on DPI 35.
(A) 37 DPI, (B) 42 DPI, (C) 63 DPI. All genes normalized to Gapdh and error bars presented as
mean RQ ± RQ max & min. N = 4-6 per group. [*] p ≤ 0.1, * p ≤ 0.05, and ** p ≤ 0.01.
Alterations in mRNA expression after delayed testosterone at subacute timepoints
after injury. To determine if the expression patterns associated with testosterone from Fig. 4
would display sustained mRNA expression across all timepoints after treatment, a two-way
ANOVA was performed for each gene to analyze the effect of treatment (levels = 2 (rmTBI &
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rmTBI + T) vs. time (levels = 3 (37, 42, and 63 DPI)). The two-way ANOVA revealed the effect
of time was insignificant for all genes; therefore, mRNA relative expression values at all
timepoints were combined to run an unpaired two-tailed t-test analyzing the effect of treatment
regardless of chronic timepoint (Fig. 5). Combined sample sizes yielded 17-26 animals per
group. Upon the exclusion of timepoints, relative gene expression for testosterone-treated
animals indicated a significant reduction in Casp8 (0.80 +0.04/-0.04; p = 0.0054) and Nox4 (0.72
+0.08/-0.07; p = 0.0469) when compared to untreated rmTBI rats. Similarly, expression patterns
for Gsdmd (0.85 + 0.07/-0.05; p = 0.0871) and Ripk1 (0.82 +0.06/-0.06; p = 0.0690) produced
downregulations near the threshold of significance.
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Figure 5: Delayed Testosterone After rmTBI Reduces the Expression of Deleterious Genes
at Combined Timepoints Following Injury. Gene expression relative to rmTBI following
testosterone treatment for six genes in the ipsilateral vestibular nucleus pooled at chronic
timepoints (37, 42, and 63 DPI) after injury. (A) Bdnf, (B) Hspa1b, (C) Nox4, (D) Casp8, (E)
Gsdmd, and (F) Ripk1. All genes normalized to Gapdh and error bars presented as mean RQ ±
RQ max & min. N = 17-26 per group. [*] p ≤ 0.1, * p ≤ 0.05, and ** p ≤ 0.01.

CHAPTER 6
RT-QPCR VALIDATION
Establishing a Control Gene
In order to validate the timepoint-specific gene expression from Aim 1, raw Gapdh cycle
threshold (Ct) values were analyzed between all groups to identify any potential differences that
may have led to timepoint-specific gene expression. Two-way ANOVA revealed no changes
between timepoints or groups, thereby supporting the use of Gapdh as a control gene unaffected
by injury or treatment. To validate these results further, RT-qPCR was performed on the
contralateral vestibular nuclei, and Gapdh values were compared between ipsilateral and
contralateral sides (Table 2). Two-way ANOVA indicated no change between groups (sham,
rmTBI, and rmTBI + T) and no change in laterality (ipsilateral and contralateral), thereby
supporting prior evidence from our laboratory that a closed-head, 5-hit rmTBI model results in
diffuse bilateral secondary insult to the brain.
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Table 2: Validation of Gapdh Between Groups, Timepoints, and Laterality. Raw Ct values
for Gapdh expression presented between groups, timepoints, and hemispheres of the vestibular
nuclei. No significant differences were observed.

Ipsilateral
Groups
Avg. Sham ± SD
N
Avg. rmTBI ± SD
N
Avg. rmTBI + T ± SD
N

Contralateral

35 DPI

37 DPI

42 PDI

63 DPI

35 DPI

37 DPI

42 PDI

63 DPI

18.12 ±
0.18
N=6
18.18 ±
0.21
N=6
18.20 ±
0.28
N=6

17.70 ±
0.38
N=6
17.89 ±
0.31
N=6
17.46 ±
0.43
N=5

17.99 ±
0.69
N=5
18.26 ±
0.28
N=4
18.01 ±
0.17
N=6

17.83 ±
0.22
N=4
18.23 ±
0.46
N=4
17.61 ±
0.35
N=6

17.99 ±
0.38
N=6
18.11 ±
0.28
N=6
18.11 ±
0.23
N=5

18.22 ±
0.49
N=2
18.04 ±
0.44
N=4
17.66 ±
0.13
N=2

18.23 ±
N/A
N=1
18.45 ±
0.25
N=4
18.30 ±
0.08
N=3

17.57 ±
0.24
N=6
17.57 ±
0.24
N=6
17.85 ±
0.66
N=5

Bilateral Effects of Injury
Gene expression from Aim 1 revealed that rmTBI animals show significant elevations in
Hspa1b and trending elevations for Nox4 and Gsdmd when compared to sham; however, these
observations were only found in animals at 42 DPI. In order to validate if this time-specific
phenomenon was biologically authentic, or due to artifact, RT-qPCR was performed on the
contralateral vestibular nucleus to examine if the differences in ipsilateral expression would
show consistency between hemispheres. The results indicated that genes upregulated in
ipsilateral vestibular nucleus at 42 DPI showed nearly identical trends in the contralateral
vestibular nucleus at the same timepoint (Fig. 6). No statistical analysis was made between
groups due to limited contralateral sample size in the control group. While these results are
observatory, they indicate bilateral upregulation in gene expression as a result of rmTBI at
extended timepoints after injury. Furthermore, these results provide validation for the timepointspecific expression patterns found at 42 DPI by demonstrating evidence that mRNA elevations
occur bilaterally and were not due to artifact or random statistical variation.
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Figure 6: Contralateral Expression Patterns Associated with rmTBI at 42 DPI. Gene
expression patterns relative to sham in the contralateral vestibular nucleus for genes of interest
shown to be upregulated in the ipsilateral vestibular nucleus at 42 DPI. (A) Hspa1b, (B) Nox4,
and (C) Gsdmd. All genes normalized to Gapdh and error bars presented as mean RQ ± RQ max
& min. N = 1-4 per group.

Bilateral Effects of Treatment
Data from Aim 1 revealed that animals which received testosterone treatment show
significant reductions in expression for Bdft, Casp8, and Gsdmd 2 days after treatment (37 DPI)
and nearly significant reductions in expression for Hspa1b and Ripk1 2 days after treatment and
Ripk1 28 days after treatment (63 DPI); however, these results were specific to 37 and 63 DPI. In
order to validate this time-specific phenomenon, RT-qPCR was performed on the contralateral
vestibular nucleus to examine if the differences in ipsilateral expression would show consistency
between hemispheres. The results indicated that genes downregulated in the ipsilateral vestibular
nucleus after treatment at specific timepoints showed nearly identical trends in the contralateral
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vestibular nucleus (Fig. 7). Although statistical comparisons were not performed on the 37 DPI
timepoints due to insufficient sample size, these observatory results support the bilateral nature
of mRNA alterations as a result of testosterone treatment at both acute and subacute timepoints
following treatment. Furthermore, these results provide validation for the timepoint-specific
expression patterns found at 37 and 63 DPI by demonstrating that reductions in relative gene
expression were biologically relevant and likely not attributed to artifact or random statistical
variation.
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Figure 7: Contralateral Expression Patterns Associated with Delayed Testosterone
Treatment Following rmTBI. Gene expression patterns relative to rmTBI in the contralateral
vestibular nucleus for genes of interest shown to be downregulated with testosterone treatment in
the ipsilateral vestibular nucleus at 37 or 63 DPI. (A) Bdnf, (B) Casp8, and (C) Gsdmd, (D)
Hspa1b, (E) Ripk1 – 37 DPI, (F) Ripk1 – 63 DPI. All genes normalized to Gapdh and error bars
presented as mean RQ ± RQ max & min. N = 2-6 per group.

CHAPTER 7
SPECIFIC AIM 2
Aim 2: Experimental Question 2.1
What effect does a 5-hit rmTBI model have on protein expression for apoptotic, protein
misfolding, and oxidative stress pathways in the vestibular nucleus at subacute timepoints after
rmTBI?
Rationale
The purpose of this experimental question was to investigate if proteomic changes can be
detected in the vestibular nucleus at subacute timepoints after rmTBI. Similarly to Aim 1:
Experimental Question 1.1, it is important to identify differences associated with rmTBI at
extended timepoints after injury in order to better understand how sustained molecular
dysregulations may contribute to long-term TBI neuropathology. Given the mRNA changes
between sham and rmTBI animals were relatively small and specific to timepoints, the analysis
of proteins would help reaffirm the validity of differentially expressed mRNAs while providing
evidence of identifiable molecular changes in another biological format via protein expression.
Chronic molecular alteration associated with mTBI are reported to impact various forms
of apoptosis, oxidative stress, protein folding, and regeneration (Kim, J. Y. et al., 2013; Zhang et
al., 2018; Eroglu et al., 2014; Ma, M. W. et al., 2018; Krajewska et al., 2011; Wehn et al., 2021;
Liu et al., 2020; Xu, H. et al., 2020). Given that all these pathways incorporate several key
proteins, the following markers were probed via protein-specific antibodies to represent potential
49
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sustained dysfunction after rmTBI: HSPA1B, CASP3, GSDMD, and NOX4. As previously
mentioned, past work in the Foecking lab has demonstrated chronic behavioral and histological
differences related to the vestibular nucleus in animals who receive rmTBI compared to sham
(Foecking et al., 2022). This rmTBI animal model mimics the long-term vestibular impairment
seen in rmTBI patients and allows for investigation into the sustained molecular pathways that
may be responsible for differences in pathology and behavior after rmTBI in the vestibular
nucleus. Concordant with differences in mRNA expression, alterations in protein levels after TBI
are almost exclusively explored at early timepoints after injury (Rehman et al., 2019; Wu et al.,
2021; Shaheen et al., 2021; Wang, P. et al., 2021). To address this knowledge gap, his study is
the first of its kind to analyze alterations in protein expression associated with rmTBI in the
vestibular nucleus at extended timepoints after injury. In doing so, this research helps validate
the differential mRNA expression described in Aim 1, while investigating if proteomic
fluctuations can be detected in the vestibular nucleus at subacute timepoints after rmTBI.
Results
Protein levels following rmTBI at 35 and 63 DPI. In order to explore variations in
protein levels due to rmTBI at extended timepoints after injury, western blotting was performed
on the combined ipsilateral and contralateral vestibular nuclei of sham and rmTBI animals at 35
and 63 DPI (Fig. 8). Sample size for each group was 4-6 for each gene at each timepoint, except
for 35 DPI – HSPA1B, N = 2. Unpaired two-tailed t-tests with Welch’s Correction were
performed for each gene of interest at each specific timepoint to analyze the impact of rmTBI on
protein levels compared to uninjured sham. Statistical analysis was not performed on HSPA1B
due to insufficient sample size. At the 35 DPI timepoint, all protein markers revealed an increase
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as a result of injury. Notably, NOX4, an enzyme implicated in generating oxidative stress,
demonstrated a statistically significant 11.60 ± 2.73 fold increase (p = 0.0174) as compared to
uninjured sham (Fig. 8A). Other markers demonstrated lesser fold changes of 1.77 ± 1.13 for
HSPA1B (Fig. 8B), 2.18 ± 0.72 for CASP3 (Fig. 8C), and 2.16 ± 0.88 for GSDMD (Fig. 8D);
however, these upregulations were considered statistically significant. At the later 63 DPI
timepoint, nearly all protein markers demonstrated similar, but lessened, increases as a result of
rmTBI. The largest increase in fold change was for NOX4, indicating an 8.08 ± 3.94 difference
as compared to uninjured sham (Fig. 8E). More modest differences were observed for HSPA1B,
2.09 ± 0.72 (Fig. 8F), and GSDMD, 3.31 ± 1.53 (Fig. 8H). CASP3 indicated no change between
sham and rmTBI at 63 DPI (Fig. 8G). These results indicate that proteomic elevations in
deleterious pathways responsible for the generation of oxidative stress, protein misfolding, and
pyroptosis are sustained up to 63 DPI.
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Figure 8: rmTBI Induces Sustained Trends in Proteins Related to Oxidative Stress, Protein
Misfolding, and Apoptosis. Protein levels in the vestibular nucleus for various genes of interest
at 35 and 63 DPI. (A) NOX4, (B) HSPA1B, ( C) CASP3, and (D) GSDMD at 35 DPI. (E)
NOX4, (F) HSPA1B, ( G) CASP3, and (G) GSDMD at 63 DPI. Representative images are
presented below each panel. All genes normalized to -actin and error bars presented as mean
fold change ± SEM. N = 4-6 per group, except for 35 DPI - HSPA1B, N = 2. * p ≤ 0.05.
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Aim 2: Experimental Question 2.2
What effect does delayed systemic testosterone treatment for rmTBI have on protein
expression for apoptotic, protein misfolding, and oxidative stress pathways in the vestibular
nucleus?
Rationale
Testosterone, an endogenous androgen, has been shown to improve mitochondrial
function, reduce oxidative stress, dampen neuroinflammation, and promote neurogenesis in
animal models (Carteri et al., 2019; Wang, L. et al., 2019; Yang et al., 2020; Byers et al., 2012;
Kurth et al., 2014; Spritzer & Galea, 2007). Androgen receptors, the canonical receptors of
testosterone, are found throughout and brain, and in the vestibular nucleus (Grassi et al., 2013),
therefore is proposed that testosterone may contribute to neurotherapeutic protein changes in
animal models of rmTBI. Previous work in this thesis demonstrated that delayed testosterone
altered gene expression so this experimental question addresses whether testosterone treatment
will subsequently alter protein levels in an experimental model of rmTBI.
Much of the current research in testosterone therapy after TBI centers around acute
timepoints after injury. Nonetheless, acute time frames do not correspond to the clinical
recommendations associated with mTBI, nor do they explore the effect of testosterone using
delayed treatment paradigms. Given that patients with chronic vestibular impairment typically
wait weeks to months before seeking or receiving treatment, it is critical to investigate the role of
testosterone at extended subacute timepoints after injury. Previous work in the Foecking Lab has
demonstrated that delayed testosterone treatment after rmTBI effectively ameliorated vestibular
behavioral deficits associated with injury (Segismundo, 2019); however, these functional
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changes were not observed until 28 days following treatment (63 DPI). As a result, this work
aimed to investigate the molecular underpinnings of how delayed testosterone acts as a
neurotherapeutic at this extended timepoint after injury. This study is the first of its kind to
investigate protein levels associated with delayed testosterone treatment in the vestibular nucleus
after rmTBI. In doing so, it explores the potential molecular mechanism by which testosterone
acts as a neurotherapeutic in a clinically relevant rodent model for rmTBI.
Results
Protein levels following delayed testosterone treatment in rmTBI. In order to
investigate the impact of delayed testosterone on protein levels in a closed-head rmTBI model,
western blotting was performed on the vestibular nuclei of rmTBI treated and rmTBI untreated
animals 28 days after testosterone treatment at 63 DPI (Fig. 9). Unpaired two-tailed t-tests with
Welch’s Correction were carried out for each gene of interest to analyze the effect of delayed
testosterone treatment. While results were not statistically significant, they revealed that
testosterone seems to reduce levels of deleterious proteins upregulated with injury. Nearly 70%
decreases in fold change were observed for NOX4, 0.36 ± 0.09 (Fig. 9A), and GSDMD, 0.38 ±
0.06 (Fig. 9D) when compared to untreated rmTBI animals. More modest, 50% decreases were
observed for HSPA1B, 0.53 ± 0.16 (Fig. 9B), and CASP3, 0.59 ± 0.11 (Fig 9C) for animals
treated with testosterone. These results indicate that testosterone reduces the levels of markers
for oxidative stress, protein misfolding, apoptosis, and pyroptosis, even when administered 35
days after rmTBI.
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Figure 9: Delayed Testosterone Treatment Produces Decreased Trends in Proteins Related
to Oxidative Stress, Protein Misfolding, and Apoptosis. Protein levels in the vestibular
nucleus for various genes of interest 28 days after testosterone treatment. (A) NOX4, (B)
HSPA1B, ( C) CASP3, and (D) GSDMD at 63 DPI. Representative images presented below each
panel. All genes normalized to -actin and error bars presented as mean fold change ± SEM. N =
4-6 per group.

CHAPTER 8
DISCUSSION
The primary injury associated with mTBIs is known to initiate a heterogeneous cascade
of pathophysiological processes that all differ in temporal profiles (Wang, K. K. et al., 2018).
While this cascade has been studied in mTBI, the molecular sequelae associated with rmTBI are
still a relatively novel topic of interest. Given the nuances specific to repetitive mild injuries, the
temporal profile of molecular pathways initialed after injury may be similar but inherently
different from mTBI, perhaps due to repetitive impacts in the vulnerable recovery period leading
to compounding or longer-term effects (McCrea et al., 2009). The research in this thesis is the
first to investigate the long-term molecular alterations associated with rmTBI in the vestibular
nucleus. While studies have explored the impact of rmTBI on more common brain regions such
as the hippocampus or cortex (Shaheen et al., 2021; Song et al., 2016) investigating rmTBI in the
vestibular nucleus is necessary as vestibular impairment (Marcus et al., 2019) and neuronal cell
death have been exhibited in the vestibular nucleus following rmTBI (Foecking et al., 2022).
Furthermore, this work builds on previous finding demonstrating that delayed testosterone
treatment reduced vestibular impairment following rmTBI and improved cell survival in the
vestibular nucleus (Foecking et al., 2022). While those results corroborate literature
demonstrating the therapeutic efficacy of testosterone (Yang et al., 2020; Wang, L. et al., 2019;
Spritzer & Galea, 2007), the findings in this study demonstrate the molecular alterations
associated with delayed testosterone in rmTBI. Although investigating extended timepoints after
56
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rmTBI is typically associated with minimal results (Witcher et al., 2021; Huynh et al., 2020), a
delayed paradigm was justified due to the clinical prevalence of patients seeking treatments for
persisting symptoms at extended timepoints after injury. This study innovatively explores rmTBI
from a clinically relevant perspective and investigates the novel molecular alterations associated
with injury and delayed testosterone in the context of rmTBI.
The elevated presence of enzymes responsible for the generation of oxidative stress has
been well documented in TBI (Khatri et al., 2018; Huang et al., 2020) but is not explicitly
understood in repeat mild injuries. Elevations in NADPH oxidases, nitric oxide synthases, and
catalases have all been shown in TBI rodent models but only at acute and early subacute
timepoints after injury (Ma, M. W. et al., 2018; Xu, J. et al., 2018; Huang et al., 2020). The
results of this thesis corroborate current literature by demonstrating marked increases in Nox4
gene expression after injury but reveal a unique pattern of upregulation specific to 42 DPI that
was validated with similar results in the contralateral hemisphere. Some pathways associated
with mTBI, such as apoptosis and necrosis, have a biphasic temporal profile, indicating an initial
elevation early after injury and another elevation later after injury (Bramlett & Dietrich, 2015). A
dual response is thought to be attributed to pathways occurring at different timepoints among
various cell types after insult (Lotocki et al., 2011; Flygt et al., 2013). Since the temporal profile
of oxidative stress in rmTBI is widely unknown, the findings of this study suggest that oxidative
stress may become elevated at extended timepoints after injury or perhaps persist longer due to
the effect of multiple impacts. These results refute findings that Nox4 returns to baseline at 14
DPI (Ma, M. W. et al., 2018); however, those observations were specific to one singular TBI of
mild severity. Conflicting findings for a similar marker demonstrate the stark contrast in
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pathology between the deleterious effects of a less severe but repetitive TBI model compared to
that of a more severe singular impact model. Additionally, the timepoints specific alteration in
this thesis may be attributed to the wide range of symptoms associated with rmTBI, suggesting
that animals will also experience a wide range of differences in molecular profiles even with
identical repetitive impacts. Our observations match clinical data on mTBI, which suggest that
most patients gradually recover with time, while others will experience a prolonged recovery
period that extends past one month post-injury (McCrea et al., 2009), indicating that the 42
cohort of animals may have had a worsened and extended response to rmTBI.
Protein data is considered to be a functional consequence of alterations in transcription
(Greenbaum et al., 2002). A study investigating the impact of TBI on NOX4 protein supports the
transcriptional increase observed in the Nox4 findings of this thesis; however, those results were
specific to acute time points after injury and did not utilize a repetitive model (Ma, M. W. et al.,
2018). The protein analysis in this work extends the findings of Ma et al. by demonstrating that
NOX4 is statistically elevated up to 35 DPI and still shows a large elevation up to 63 DPI.
Interestingly, the protein results for NOX4 differ from the timepoint-specific results found in the
mRNA analysis. While this lack of association may be surprising, it is not uncommon to have
transcriptional and proteomic variations. Large-scale correlational studies often report only a
30% correlation between mRNA and protein, attributing the majority of variance to posttranscriptional and post-translational regulation and measurement errors (de Sousa Abreu et al.,
2009). The presence of both mRNA and protein is highly indicative of a pathway being
biologically relevant within a respective model. Taken together, the mRNA and protein
elevations for an established marker of oxidative stress are elevated in the vestibular nucleus
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following rmTBI at extended time points after injury. Thereby, targeting pathways that generate
oxidative stress may be an effective therapeutic strategy for individuals suffering from vestibular
dysfunction as a result of rmTBI.
Testosterone treatment following severe CCI-induced TBI in mice has been shown to
reduce the generation of hydrogen peroxide and total ROS in the ipsilateral cortex when
compared to vehicle-treated controls (Carteri et al., 2019); however, the impact of delayed
testosterone in a rmTBI model, and specifically in the vestibular nucleus, remains widely
unknown. The results of this thesis support evidence that testosterone reduces oxidative stress in
TBI but innovatively show that it can ameliorate oxidative stress even when administered 35
days after insult. Furthermore, the mRNA data associated with testosterone treatment also
indicated a trend toward downregulation that was maintained at every timepoint in this study.
Collectively, these results demonstrate that delayed testosterone may play a role in the reduction
of markers that generate oxidative stress in the vestibular nucleus following rmTBI. These
findings should be investigated further to better understand the impact of testosterone on other
markers that generate and reduce oxidative damage within the context of rmTBI. Targeting longterm oxidative stress may be a relevant strategy for alleviating persistent symptoms associated
with rmTBI.
Protein misfolding, or a lack of proteostasis, can have severe consequences on the normal
function of a healthy cell and ultimately act as a precursor to cellular death (Daugaard et al.,
2007). Given that proper protein folding is dependent on several criteria ranging from pH to
temperature, an insult such as mTBI has been shown to induce cellular stress and thereby result
in a lack of proteostasis (Brady et al., 2021). Others have demonstrated that inducing the
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translation of heat shock protein 70 helps reduce the neurological consequences of TBI measured
through improvement in neurological severity scores and Morris water maze testing (Zhang et
al., 2018). The work in this thesis contributes to the findings of Zhang et al. by demonstrating
transcriptional and proteomic elevations in HSPA1B, an inducible member of the heat shock
protein 70 family, following rmTBI. The elevation in HSPA1B at extended timepoints after
injury indicates a lack of protein homeostasis and consequently an increase in protein misfolding
as a result of rmTBI. Similar to the oxidative stress data, mRNA elevations were heightened at
42 DPI, while HSPA1B protein showed a consistent elevation at 35 and 63 DPI. Since the
transcriptional elevation was at the same timepoint as the increase in oxidative stress, the
elevated generation of ROS associated with oxidative stress may have contributed to the rise in
the protein misfolding measured via HSPA1B.
This study is the first of its kind to analyze the impact of testosterone on HSPA1B. It was
hypothesized that delayed testosterone treatment would reduce cellular stress and thereby reduce
levels of HSPA1B. The results of this thesis partially support this hypothesis by demonstrating
that delayed testosterone had an early effect that reduced mRNA encoding Hspa1b at 2 days
following treatment, but the reduction was not maintained at the later timepoints of this study.
This acute effect may be due to the activation of mAR, which is known to act via a rapid
timeframe compared to the traditional nuclear AR. Future investigations into the temporal
changes associated with testosterone treatment should consider analyzing earlier timepoints posttreatment as this paradigm does not account for alterations within the first 48 hours following
testosterone administration. Protein levels for HSPA1B were markedly decreased 28 days
following testosterone administration. Ultimately, these results indicate that persistent protein
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misfolding in the vestibular nucleus is a long-term consequence of rmTBI and that testosterone
treatment alleviates the induction of markers associated with protein misfolding. These results
warrant future studies aimed at analyzing the effect of rmTBI and testosterone on other members
of the heat shock protein family to better understand if targeting improper protein folding may be
therapeutically efficacious treatment at clinically relevant timepoints after rmTBI.
A chronic inflammatory response is generally regarded as a negative outcome of an insult
or injury (Medzhitov, 2008). Others have demonstrated that mTBI increases inflammatory
markers at various timepoints after injury (Chaban et al., 2020); however, the temporal profile of
this inflammatory response is not well defined in the context of rmTBI. Moreover, others have
observed that TBI leads to an increase in pyroptosis, an inflammatory mediated form of cell
death (Sun et al., 2020). The results of this thesis strengthen the literature stating that pyroptosis
is upregulated in TBI, and are the first to show that GSDMD, a pyroptotic mediator, is
upregulated up to 63 DPI in the vestibular nucleus utilizing a closed-head rmTBI model.
Elevated levels of GSDMD indicate the presence of long-term inflammation and subsequence
cell death, which correspond to the histological cell data from previous work showing rmTBI
leads to a reduction in neurons in the vestibular nucleus (Foecking et al., 2022). The
transcriptional results for Gsdmd were specific to the 42 DPI timepoint, just as Nox4 and
Hspa1b, indicating that the presence of oxidative stress and protein misfolding may be correlated
to the increase in pyroptosis seen with injury at this specific timepoint. Protein results for
GSDMD were consistent with NOX and HSPA1B, signifying a sustained elevation in GSDMD
at 35 and 63 DPI. These observations further support the notion that pyroptosis is associated with
oxidative stress and protein misfolding. The transcriptional and proteomic elevations for
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GSDMD reveal that pyroptosis is implicated in rmTBI at extended timepoints after injury and
that targeting this pathway may therapeutically ameliorate inflammatory mediated cell death in
the vestibular nucleus following rmTBI.
This study is the first to examine the effect of testosterone treatment on pyroptosis in the
vestibular nucleus using an experimental model of rmTBI. These results indicate that delayed
testosterone treatment 35 days after the onset of injury has therapeutic efficacy in reducing
inflammatory mediated cell death. Delayed testosterone produced a biphasic transcriptional
effect that reduced mRNA encoding Gsdmd at 2 days after treatment and, to a lesser extent, 28
days after treatment, but not in the intermediate timepoint of 7 days after treatment. These
findings further support the interrelated nature of oxidative stress and protein misfolding data
and highlight the broad range of pathways that testosterone is able to modulate following delayed
administration. Protein data revealed that delayed testosterone treatment produced a substantial
decrease in GSDMD when measured 28 days following treatment. A decrease in GSDMD
correlates to a reduction in pyroptosis, which corroborates the amelioration in neuronal cell death
in the vestibular nucleus following testosterone treatment exhibited in past research in the
Foecking Lab. While this thesis investigates GSDMD, it must be noted that cleaved GSDMD is
responsible for the destructive nature associated with pyroptosis; however, literature
demonstrates a correlation between GSDMD and cleaved GSDMD, indicating that an increase in
full-length protein is associated with an elevation in the cleaved product (Sun et al., 2020; Wang,
P. et al., 2021). Collectively, the results from this work indicate that pyroptosis is an active
pathway in closed-head rmTBI, even up to 63 DPI. The administration of delayed testosterone
can reduce the activity of markers for pyroptosis and therefore become therapeutically
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efficacious for individuals suffering from vestibular impairment due to rmTBI. Further
investigations into the temporal profile of pyroptosis should be explored by examining other
proteins involved in this pathway to determine if targeting specific mediators of pyroptosis can
be a viable treatment strategy for rmTBI.
The induction of apoptosis after TBI is shown to occur almost immediately after primary
injury (Fehily et al., 2017). Previous data demonstrated that significant neuronal loss occurred in
the vestibular nucleus 6 months after insult (Foecking et al., 2022); therefore, investigating the
role of apoptosis at extended timepoints after insult is a prominent topic of interest. The
transcriptional data demonstrated no change in Casp8, a marker for extrinsic apoptosis, at any of
the extended timepoints after rmTBI. While others have demonstrated that Casp8 is upregulated
after moderate TBI, those results were only observed up to 14 DPI (Beer et al., 2001). The
results of this work go beyond 14 DPI and indicate that extrinsic apoptosis is not upregulated at
extended timepoints after injury and therefore not a specific target for delayed treatments.
Furthermore, it has been shown that the general apoptotic mediator CASP3 is elevated after
mTBI (Tweedie et al., 2007). This thesis supports the elevation in CASP3 but is the first to
demonstrate that this elevation extends to 35 DPI in the context of rmTBI. Collectively, these
findings indicate that specific caspases known to mediate apoptosis have varying temporal
profiles in rmTBI and that targeting pro-apoptotic pathways may be therapeutically effective in
reducing rmTBI-related symptomology.
Testosterone has been shown to reduce the transcription and translation of pro-apoptotic
markers (Carteri et al., 2019). While the results of this work demonstrate that extrinsically
mediated apoptosis is not substantially elevated at extended timepoints after injury, a reduction
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in mediators responsible for programmed cell death still may still be of neurotherapeutic benefit
following rmTBI. Our findings corroborate current literature showing that testosterone reduces
caspases involved in apoptosis following TBI (Carteri et al., 2019); however, they are the first to
show that this reduction extends up to 28 days following delayed testosterone treatment in the
vestibular nucleus following rmTBI. Transcriptionally, Casp8 showed a biphasic reduction 2
days and 28 days after treatment, but not 7 days after treatment. It is known that testosterone can
act on two main classes of ARs, nongenomic mARs and nuclear ARs, both of which have
different timeframes and modulatory effects. While the influence of testosterone on mAR is not
explicitly understood, it is known that mAR responses are associated with rapid activation
compared to nuclear AR (Papadopoulou et al., 2008). It is hypothesized that the impact of
testosterone 2 days after treatment is attributed to the mAR activation, while the effects seen 28
days after treatment may be attributed to the longer-term nuclear AR. Nonetheless, this study
does not investigate one class of AR specifically, nor does it take into consideration the
aromatization of testosterone into estrogen, so these results warrant the need for additional
research into receptor specificity for gonadal steroids.
The protein data in this thesis demonstrates a reduction in CASP3 by nearly half 28 days
after treatment. This data aligns with current literature showing that CASP3 is reduced following
androgen treatment in vitro with BV2 cells and primary microglia (Yang et al., 2020) but refutes
older findings indicating that testosterone upregulates apoptosis in a dopaminergic N27 cell line
(Cunningham et al., 2009). While our study is the first to demonstrate the effect of testosterone
on various caspases in an in vivo delayed model of rmTBI, the current literature reveals the stark
contrast that testosterone treatment may have on multiple cell types, thereby stressing the
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importance of additional research for based on cell specificity. Taken together, this thesis
demonstrated that transcriptional markers for external apoptosis were not elevated with injury in
a rmTBI model; nonetheless, the broad nature of testosterone seems to downregulate apoptotic
mediators, which may contribute to the neurotherapeutic effect of testosterone treatment in
rmTBI. These findings warrant further investigation into the temporal profile of apoptosis and
other mediators that may be responsible for cell death in the vestibular nucleus following rmTBI.
The inhibition of necroptosis has been shown to restore functional outcomes in TBI (Wu
et al., 2021). Activation of necroptosis can have severe consequences after injury due to the
release of cellular contents that have a deleterious effect on the surrounding cellular environment
(Yu et al., 2021). This thesis demonstrates that necroptotic mediator Ripk1 was upregulated in a
closed-head model of rmTBI, but only at the latest timepoint of 63 DPI. These molecular
findings indicate that necroptosis may have a longer temporal profile in rmTBI or that
necroptosis may be occurring in specific population cells at extended timepoints after injury,
similarly to apoptosis. Since 63 DPI was the latest timepoint in this study, our results invite
future investigations examining the impact of rmTBI at chronic timepoints after injury.
Testosterone treatment had a biphasic reduction in Ripk1 that was specific to 2 days and 28 days
after treatment, analogous to Casp8. This temporal phenomenon is hypothesized to be attributed
to the action of mAR and AR, respectively; however, it could also be associated with the
upregulation in apoptosis, as various forms of cell death have parallel and interacting
biochemical cascades. Although results indicate that necroptosis was not elevated with injury at
many of the earlier timepoints, testosterone was shown to reduce mediators of necroptosis even
when administered at delayed timepoints after rmTBI, which could still be therapeutically
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relevant for individuals presenting with lingering vestibular impairment at extended timepoints
after insult.
Neurogenesis is known to occur at later timepoints after mTBI (Wang, K. K. et al., 2018).
The induction of neurogenesis has been shown to reduce the severity of injury and improve
outcomes after mTBI (Xu, H. et al., 2020). Our results show that gene expression for Bdnf was
unaltered at extended time points after rmTBI. These observations refute a current study
reviewing transcriptional downregulations with TBI; however, many of the downregulations in
that review were observed in single-hit models and within various brain regions such as the
hippocampus and cortex (Gustafsson et al., 2021). Given that differential expression is observed
based on brain region in the rodent brain following mTBI and that brainstem results are less
pronounced than other brain regions (Huynh et al., 2020), it was expected that results in the
vestibular nucleus, located in the brainstem, would be inherently different from the published
results of other brain regions. Interestingly, the introduction of delayed testosterone reduced the
transcription of Bdnf 2 days after treatment, but this decrease was not maintained at the later time
points of this study. While the data in this thesis refute published findings indicating that
testosterone increases levels of BDNF; it must be noted that those results were specific to the
hippocampus and did not utilize a rmTBI-specific injury model (Jia et al., 2016). Similar to other
genes in this thesis, acute results for BDNF expression may be attributed to the detrimental
actions of mAR and membrane estrogen receptor activation at early time points upon
testosterone administration; however, they cannot be confirmed as the molecular cascades
associated with membrane receptors are still a relatively novel topic of interest. While the downregulation of Bdnf may not contribute to the neurotherapeutic effects of testosterone, the
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reduction in detrimental markers for apoptotic and cellular stress pathways that coincide with
Bdnf downregulation may outweigh these results when determining if testosterone can have
therapeutic efficacy as a treatment strategy for rmTBI.
The results of this thesis are the first to explore transcriptional and proteomic expression
patterns more than a month after closed-head rmTBI in the vestibular nucleus. Our findings
indicate that rmTBI induces upregulation of transcriptional and proteomic markers for rmTBI for
pyroptosis, oxidative stress, apoptosis, and protein misfolding up to 63 DPI and that some of
these markers demonstrate timepoint-specific elevations that were previously unexplored.
Concurrently, delayed testosterone treatment, when given 35 days after the final rmTBI, exhibits
neurotherapeutic properties by reducing transcriptional and proteomic markers for pyroptosis,
oxidative stress, apoptosis, and protein misfolding. In summary, these results provide insight into
the molecular sequelae associated with rmTBI and indicate that delayed testosterone ameliorates
the sustained molecular consequence of injury by modulating several long-term biochemical
processes involved in rmTBI.

CHAPTER 9
LIMITATIONS
While the approach for this thesis proposal has yielded interesting and exciting results
thus far, the limitations of this work must be considered when drawing conclusions to guide
future investigations. Evidently, one of the largest limitations in this thesis is the selection of
molecular markers representative of various pathways associated with injury and treatment.
Although all markers were specifically chosen based on an extensive literature review, it was
anticipated that some of the chosen markers may not significantly change as a result of insult or
treatment, especially via this delayed and clinically relevant closed-head mild paradigm. The
biochemical neuropathology associated with TBI is extremely multifaceted and filled with
heterogeneous signaling cascades that differ in temporal profile after injury While a lack of
significance for given markers of various pathways was observed throughout this study, this does
not necessarily eliminate the involvement of those signaling pathways in the context of rmTBI as
other members within a biochemical cascade may yield alternative results. Additionally, because
this work utilizes both mRNA and protein, both transcriptional and translational results should be
considered, with regard to their respective strengths and weaknesses, when drawing conclusions
from this thesis.
Among methodological limitations, the vestibular tissue dissection method used in this
study is not the most precise method of isolating the vestibular nucleus. Since the vestibular
nucleus is extremely small in volume, tissue punches could have incorporated other surrounding
68

69
tissues which may result in inconsistent molecular alterations associated with injury and
treatment. A more precise method, such as laser microdissection would have yielded more
accurate vestibular results, however, due to limitations with time, this collection method was not
an option for this thesis. The size of the vestibular nucleus in rat also gave rise to the decision to
combine both contralateral and ipsilateral nuclei for protein analysis, given the minimum total
protein need for western blotting. Proteomic approaches may be better suited to identify protein
changes in ipsilateral and contralateral vestibular nuclei separately. However, previous work
utilizing this rmTBI model has shown to produce bilateral histological alteration in both the
ipsilateral and contralateral vestibular nuclei, therefore the combination of samples was justified.
Minimal protein samples subsequently reduced the ability to analyze every gene of interest with
a corresponding protein. Given that transcriptional and translation correlations are known to
vary, it is possible that proteins for genes that were not analyzed through western blotting could
have yielded significantly different results compared to the mRNA findings. Furthermore, factors
such as unexpected animal death and loss of samples during purification, which contributed to
the low sample size for single timepoint analysis between various groups were all unanticipated
difficulties that were overcome to produce this data. Regardless, due to limitations and time, the
current group sizes were deemed sufficient to investigate preliminary molecular changes,
especially given the lack of literature on molecular differences at such extended timepoints using
a closed-head rmTBI delayed treatment paradigm.
A large methodological limitation of this study was the use of TRIzol Reagent to obtain
both mRNA and protein from the same sample. Although using TRIzol can provide high yield of
total RNA, protein extraction using TRIzol can be challenging and result in low protein yields.
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As a result, the protein data within this thesis underwent multiple TRIzol extractions, additional
ethanol purifications, and literature based TRIzol modifications to aid in the solubilization of
proteins. The addition of these processing and purification steps was necessary to obtain protein
data for this thesis; however, it must be noted that this additional processing likely contributed to
the lack of uniformity between protein samples. Nonetheless, the difference in protein was
accounted for via densitometric analysis using an internal control for each sample, which was
performed in this study using β-actin, a common gene used in both mTBI and testosterone
treatment literature (Rehman et al., 2019; Mei et al., 2018; Carteri et al., 2019; Wang, L. et al.,
2019).
Another limitation of this study was the lack of receptor specificity by which delayed
testosterone treatment may be modulating transcription and translation. While the introduction of
an endogenous androgen would likely act through both nuclear ARs and nongenomic mARs, it
must also be noted that testosterone can become aromatized into estradiol, an endogenous
estrogen, via aromatase cytochrome P450, and thereby elicit effects through estrogen receptors
which have been shown to be present in the vestibular nucleus (Simpson, 1994). Similar to
testosterone, estrogens have also been shown to demonstrate a variety of neurotherapeutic effects
that could be responsible for the functional recovery associated with this model of rmTBI. As
this study does not introduce an aromatase inhibitor or use an androgen that is less likely to be
metabolized into estrogen, such as dihydrotestosterone, the results cannot be solely attributed to
testosterone. Nonetheless, testosterone was specifically chosen due to its metabolic ability to
become aromatized and potentially act as an estrogen if biochemically needed, thereby
increasing its potential to act as a therapeutic under conditions of insult or cellular stress. While
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having wide therapeutic efficacy is beneficial, a lack of targeted receptors is also accompanied
by a wide range of side effects, as in the case of acute downregulations with Bdnf as a result of
treatment. These results are likely attributed to membrane androgen and membrane estrogen
receptors which are a rising field of interest with initial in vitro data indicating that membrane
androgen activation suppresses transcription of pro-survival factors in prostate cancer cells
(Papadopoulou et al., 2008). This emphasizes the importance of future explorations on the effects
of testosterone across all its potential mechanisms when determining its efficacy as a delayed
therapeutic in the case of rmTBI.
A minimal limitation in this study may be the slight difference in anesthesia between
cohorts on animals euthanized across varied timepoints. While this was indented to be kept
identical, there were minor differences among timepoints, but not within the groups of animals
for each timepoint. Since anesthesia is known to affect mRNA expression in TBI animal models
(Staib-Lasarzik et al., 2014), these differences could influence transcriptional results and thereby
contribute to the timepoint-specific gene expression seen with injury and testosterone treatment.

CHAPTER 10
CONCLUSIONS
The focus of this present work was aimed at identifying the molecular sequelae
associated with closed-heard rmTBI in the vestibular nucleus at extended timepoints after insult
and investigating the molecular means by which testosterone acts as a neurotherapeutic when
administered 35 days after rmTBI. This aim was explored by analyzing the transcriptional and
proteomic patterns of several gene products and pathways shown to be involved in rmTBI and
testosterone treatment. These results indicate that rmTBI induces detectable elevations of mRNA
and proteins involved in the generation of oxidative stress, maintenance of proteostasis, and
induction of both apoptosis and pyroptosis at extended timepoints ranging from 35 to 63 DPI.
These novel findings highlight the widely unexplored temporal timeframe associated with
rmTBI. They indicate that several deleterious processes extend into months past the insult which
are thought to be responsible for the sustained vestibular neuropathology in this model and
ultimately long-term vestibular impairments. Interestingly, the administration of testosterone at
35 DPI induces a biphasic, temporally acute and subacute reduction in the transcription and
translation of markers for oxidative stress, protein misfolding, and inflammatory mediated cell
death, all of which were elevated with rmTBI alone. These innovative findings challenge the
standard paradigm of introducing treatments directly after mTBI and provide exciting results for
individuals living with sustained vestibular impairment. By focusing this research on a clinically
relevant rodent model of delayed testosterone treatment following closed-head rmTBI in the
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vestibular nucleus, this thesis deciphers the ways by which testosterone acts to ameliorate the
sustained consequences of injury. This clinically relevant work will aid future research into the
development of biomarkers for rmTBI and guide novel studies investigating delayed treatment
paradigms or pharmaceutical interventions aimed at alleviating long-term symptoms associated
with mTBI.
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